Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417423 | 0.97 | ADORA2A (0.49) | ADORA2AADORA1 | |
| SCHEMBL5418710 | 0.87 | ADORA2A (0.45) | ADORA2AADORA1 | |
| SCHEMBL5415968 | 0.85 | ADORA2A (0.66) | ADORA2AADORA1 | |
| SCHEMBL5405863 | 0.83 | ADORA2A (0.48) | ADORA2AADORA1 | |
| SCHEMBL3188559 | 0.81 | ADORA2A (0.70) | ADORA2AADORA1 | |
| SCHEMBL6201288 | 0.81 | ADORA2A (0.55) | ADORA2AADORA1 | |
| SCHEMBL5421826 | 0.76 | ADORA2A (0.41) | ADORA2AADORA1 | |
| SCHEMBL5413254 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1 | |
| SCHEMBL5413654 | 0.75 | ABCB1 (0.55) | ADORA2AADORA1 | |
| SCHEMBL5413226 | 0.75 | ABCB1 (0.59) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285550-B2 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2007-10-23 | — | — | US | claimed |
| US-20060276475-A1 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-12-07 | — | — | US | claimed |
| US-7285550-B2 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20060276475-A1 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | BIOGEN IDEC MA INC. | 2006-12-07 | — | — | US | disclosed |
| EP-1615930-A2 | TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGONISTS | Biogen Idec MA, Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092170-A2 | TRIAZOLOTRIAZINES AND PYRAZOLOTRIAZINES USEFUL AS A2A ADENOSINE RECEPTOR ANTAGON ISTS | BIOGEN IDEC MA INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276475-A1 | Triazolotriazines and pyrazolotriazines and methods of making and using the same | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.